Tuberous sclerosis

XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease

Retrieved on: 
Tuesday, December 21, 2021
TSX Venture Exchange, Multicystic dysplastic kidney, News, GLOBE, Fortis Healthcare, No, Treatment, Autosome, Therapy, Medullary sponge kidney, Kidney, Liver disease, Health, Kidney disease, Uric acid, Sirna, Method, Hypertension, CEO, Unitary state, ADPKD, Form, ARPKD, Security (finance), Islamic Republic News Agency, U.S. Securities and Exchange Commission, Xanthine oxidase, COVID-19, Diagnosis, Diabetic nephropathy, Research, NASDAQ, Publishing, Disease, Endothelial dysfunction, Quality of life, Cardiovascular disease, Dysplasia, Polycystic kidney disease, Chronic kidney disease, Company, Patent, SEC, Cystic fibrosis, Von Hippel–Lindau disease, Coronavirus, Patient, Tuberous sclerosis, Analysis, Pharmaceutical industry, Nasdaq

The Company remains dedicated to redefining kidney disease in the future and advance our lead program XRx-008 - on behalf of individuals with progressing kidney disease due to autosomal dominant polycystic kidney disease.

Key Points: 
  • The Company remains dedicated to redefining kidney disease in the future and advance our lead program XRx-008 - on behalf of individuals with progressing kidney disease due to autosomal dominant polycystic kidney disease.
  • Polycystic Kidney Disease is characterized by an array of anatomic and physiologic abnormalities, for example hypertension, endothelial dysfunction, cardiovascular disease, liver disease, cardiovascular disease involving large, medium and small caliber blood vessels as well as other health problems are frequently encountered by patients with polycystic kidney disease.
  • Polycystic kidney disease is associated with genetic changes and described by two categories- autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD).
  • ADPKD is leading cause of polycystic kidney disease is autosomal dominant polycystic kidney disease and contributes approximately 90% of all individuals.

Nobelpharma America Announces Presence at 75th American Epilepsy Society Annual Meeting

Retrieved on: 
Monday, November 29, 2021
United States, Skin, Chin, Red, CEO, Neurology, MD, Tuberous sclerosis, University, Faculty, Lists of diseases, Physician, Treatment, Dermatology, LLC, TSC, Bleeding, Hamartoma, Diagnosis, Importance, NPA, Pediatrics, Learning, Multimedia, American Epilepsy Society, Epilepsy, Medical Center, Disease, Itch, Degenerative disease, Nose, The, Autism, Pharmaceutical industry

BETHESDA, Md., Nov. 29, 2021 /PRNewswire/ -- Nobelpharma America, LLC, a pharmaceutical and medical device company headquartered in Bethesda, Maryland, today announced its attendance at the American Epilepsy Society 2021 Annual Meeting, December 3-7, 2021. In addition to an exhibit booth, the company is hosting a satellite symposium to discuss a multidisciplinary approach in identifying the cutaneous manifestations of Tuberous Sclerosis Complex (TSC) and further understanding the impacts the disease has on individuals living with TSC. 

Key Points: 
  • Our presence atthe American Epilepsy Society Annual Meetingwill help us learn from the physicians who are diagnosing facial angiofibroma associated with TSC,a disease that has limited treatment options and is often overlooked due to the small number of individuals affected."
  • Nobelpharma is hosting the satellite symposium entitled, "Establishing the Importance of a Multidisciplinary Approach in the Diagnosis and Treatment of Tuberous Sclerosis Complex and Its Cutaneous Manifestations."
  • Nobelpharma America, LLC (NPA) is focused on the commercialization of pharmaceuticals and medical devices that expand treatment options for people with rare diseases.
  • In 2019, NPA became the first wholly ownedglobalsubsidiary of Nobelpharma Co., Ltd., which is based in Tokyo.

Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results

Retrieved on: 
Wednesday, November 10, 2021
Neurology, Three Months Gone, Director, Security (finance), COVID-19, Angelman syndrome, Acquisition, Lists of diseases, Therapy, Risk, Dravet syndrome, Seizure, Genetics, GABA, Acceleration, Lennox–Gastaut syndrome, Fragile X syndrome, Technology, NEW, Research, Forward-looking statement, Tuberous sclerosis, U.S. Securities and Exchange Commission, GLOBE, GAAP, Patient, Science, Brain, Sirna, Alnylam Pharmaceuticals, NASDAQ, Knowledge, RNA interference, SEC, Drug discovery, Budget, Neuroscience, RNA, Senior, CNS, Board, Company, MB, KIF1A, IND, Pharmaceutical industry, Management, Lease

Ovid reported its strategic intent to pursue a series of business development opportunities aimed at complementing and enhancing its pipeline of small-molecule and next-generation medicines.

Key Points: 
  • Ovid reported its strategic intent to pursue a series of business development opportunities aimed at complementing and enhancing its pipeline of small-molecule and next-generation medicines.
  • Ovid conducted a strategic review of approximately 100 potential programs and confirmed desired areas of business development to apply its capital and expertise.
  • Ovid will seek to create best-in-class or first-in-class medicines that can have a meaningful impact on patients.
  • Ovid expects non-GAAP adjusted operating expenses to remain within the $8.0 - $10.0 million range for the fourth quarter of 2021.

Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors

Retrieved on: 
Thursday, October 7, 2021
NASDAQ, Lists of diseases, The New England Journal of Medicine, Brain, Forward-looking statement, Lennox–Gastaut syndrome, Risk, Therapy, RNA interference, GABA, Angelman syndrome, Drug discovery, MB, COVID-19, Alnylam Pharmaceuticals, Sirna, Genetics, GLOBE, Board of directors, Seizure, SEC, Research, Board, Bristol Myers Squibb, KIF1A, Tuberous sclerosis, U.S. Securities and Exchange Commission, Dravet syndrome, Mace Head Atmospheric Research Station, RNA, Senior, Degenerative disease, CNS, Patient, Technology, Takeda, Pharmaceutical industry

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors.

Key Points: 
  • NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors.
  • We are very pleased to have Kevin join our Board of Directors.
  • Kevins expertise across small molecule and next-generation modalities makes him an ideal director for Ovid as we pursue innovative platforms for the development and delivery of therapeutics to the brain.
  • Ovids strategic approach to targeting and delivering therapies to the disorders of the brain bridges the technology of today with that of tomorrow, saidFitzgerald.

PsychoGenics Chief Innovation Officer Honored for Scientific Excellence

Retrieved on: 
Thursday, September 23, 2021
Technology, Mental Health, Research, Other Technology, Biotechnology, Health, Pharmaceutical, Other Science, Science, STEM, CNS, EEG, Partnership, Probability, Molecular biology, Hope, Children's Tumor Foundation, Epilepsy, Investigational New Drug, Library, Autism, Depression, USA, Patient, Engineering, Data science, Great Minds with Dan Harmon, Population, Muscular dystrophy, Sunovion, Lists of diseases, CEO, GMIS International, Columbia University, Leadership, Science, Algorithm, Cognition, Tuberous sclerosis, Intelligence, ALS, Research, Electrophysiology, Drug discovery, PTSD, Education, University of Cambridge, Organization, Psychology, Microdialysis, Digital, Neurodegeneration, Anxiety, Time, Schizophrenia, Hispanic Scientist of the Year Award, Disorder, Medical device, Pharmaceutical industry, SmartCube®–driven Drug Discovery, PsychoGenics, GMiS, SMARTCUBE®–DRIVEN DRUG DISCOVERY, PSYCHOGENICS, GMIS

PsychoGenics announces that Daniela Brunner Ph.D., Chief Innovation Officer, was named the recipient of Great Minds in STEMTM (GMiS) Scientist of the Year Award ( GMiS 2021 Award Winners ).

Key Points: 
  • PsychoGenics announces that Daniela Brunner Ph.D., Chief Innovation Officer, was named the recipient of Great Minds in STEMTM (GMiS) Scientist of the Year Award ( GMiS 2021 Award Winners ).
  • She joined PsychoGenics in 1999 where she developed preclinical tests for cognition, neurodegeneration, autism, among others.
  • She conceived of the SmartCube discovery system and worked on the development of PsychoGenics AI technologies.
  • PsychoGenics Inc. and its discovery arm PGI Drug Discovery LLC (collectively known as PsychoGenics) have pioneered the translation of rodent behavioral and physiological responses into robust, high-throughput and high-content phenotyping.

Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Tuesday, September 7, 2021

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today announced that management will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference.

Key Points: 
  • NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today announced that management will present in a virtual format at the H.C. Wainwright 23rd Annual Global Investment Conference.
  • The presentation will be made available for on-demand viewing on Monday, September 13, 2021 at 7:00 a.m. EDT.
  • Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovids business and the global economy.
  • Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

Retrieved on: 
Monday, August 16, 2021
Forward-looking statement, NASDAQ, RNA, Research and development, Tuberous sclerosis, Lennox–Gastaut syndrome, MB, Central nervous system, Angelman syndrome, Company, Lists of diseases, Brain, COVID-19, Therapy, GABA, GLOBE, AstraZeneca, Wyeth, GAAP, The Bill, Fragile X syndrome, Patient, Seizure, Operating expense, Dravet syndrome, CNS, Executive Office of the President of the United States, Budget, Genetics, Takeda, Bill & Melinda Gates Foundation, KIF1A, Pharmaceutical industry, Management

NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today reported financial results for the quarter endedJune 30, 2021.

Key Points: 
  • NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today reported financial results for the quarter endedJune 30, 2021.
  • During the second quarter of 2021, Jeffrey Rona was elevated from his role as acting chief business officer to become the chief business and financial officer.
  • Operating expenses were $14.3 million in the second quarter of 2021 and non-GAAP Adjusted operating expenses (which excludes non-recurring expenses and non-cash expenses) were $10.0 million for the second quarter, which was within the Companys guidance of $8.0 - $10.0 million for the quarter.
  • Revenue was zero during the second quarter of 2021, as it was for the same period in 2020.

TSC Alliance Applauds Release of Updated International Guidelines for Tuberous Sclerosis Complex Diagnostic and Management Recommendations

Retrieved on: 
Tuesday, August 3, 2021
Rare diseases, Autosomal dominant disorders, Autism, Biology of obsessive–compulsive disorder, Intellectual disability, Tuberous sclerosis, Abnormal psychology, Clinical medicine, Branches of biology, TSC, TSC1

SILVER SPRING, Md., Aug. 3, 2021 /PRNewswire/ --Today, the TSC Alliance announced the publication of two new papers in the prestigious Pediatric Neurology: " Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations " and " Beyond the Guidelines: How We Can Improve Healthcare for People with Tuberous Sclerosis Complex Around the World ."

Key Points: 
  • SILVER SPRING, Md., Aug. 3, 2021 /PRNewswire/ --Today, the TSC Alliance announced the publication of two new papers in the prestigious Pediatric Neurology: " Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations " and " Beyond the Guidelines: How We Can Improve Healthcare for People with Tuberous Sclerosis Complex Around the World ."
  • Tuberous sclerosis complex (TSC) causes tumors to grow in different organs and can impair their function, primarily the brain, heart, kidneys, skin and lungs.
  • "The TSC Alliance is thrilled to announce updated 'gold standards' for TSC diagnosis, surveillance and management," said President & CEO Kari Luther Rosbeck.
  • Additionally, TSC International , a consortium of organizations that support individuals with TSC around the world, penned the companion piece, "Beyond the Guidelines: How We Can Improve Healthcare for People with Tuberous Sclerosis Complex from Around the World."

Tuberous Sclerosis Alliance Evolves to TSC Alliance and Unveils New Brand

Retrieved on: 
Monday, May 17, 2021
Rare diseases, Autism, Biology of obsessive–compulsive disorder, Intellectual disability, Tuberous sclerosis, TSC, Abnormal psychology, Branches of biology, Clinical medicine

b'Today, the Tuberous Sclerosis Alliance formally unveiled a new brand and new name: TSC Alliance .

Key Points: 
  • b'Today, the Tuberous Sclerosis Alliance formally unveiled a new brand and new name: TSC Alliance .
  • Nearly one million people worldwide have TSC.\nIn 1974, four mothers of children with TSC founded the organization, originally known as the National Tuberous Sclerosis Association.
  • In 2000, the name changed to Tuberous Sclerosis Alliance to reflect the organization\'s growth and commitment to the importance of partnerships.
  • "\nThe TSC Alliance is an internationally recognized nonprofit dedicated to finding a cure for tuberous sclerosis complex while improving the lives of those affected.

Ninth Annual TSC Global Awareness Day Scheduled for May 15

Retrieved on: 
Monday, May 3, 2021
Rare diseases, Autism, Genodermatoses, Intellectual disability, Tuberous sclerosis, TSC, Abnormal psychology, Branches of biology, Clinical medicine, TSC1

b'SILVER SPRING, Md., May 3, 2021 /PRNewswire/ -- OnMay 15, the Tuberous Sclerosis Alliance (TS Alliance) will join tuberous sclerosis complex (TSC) organizations around the world to observe the ninth annual TSC Global Awareness Day .

Key Points: 
  • b'SILVER SPRING, Md., May 3, 2021 /PRNewswire/ -- OnMay 15, the Tuberous Sclerosis Alliance (TS Alliance) will join tuberous sclerosis complex (TSC) organizations around the world to observe the ninth annual TSC Global Awareness Day .
  • On this day, thousands of individuals and families affected by TSC will come together to increase public awareness of the rare disease and share their stories of hope for the future.
  • TSC Global Awareness Day is sponsored internationally by Tuberous Sclerosis Complex International (TSCi), a worldwide consortium of TSC organizations of which the TS Alliance is a member.\nThe TS Alliance will also help celebrate the day by hosting the Step Forward to Cure TSCGlobal Virtual Walk-Run-Ride on May 15 and 16.
  • TSC Global Awareness Day is a key event to help us inform the public at large about the disease, but more importantly we hope to reach those who may not be properly diagnosed yet.